TrkB antibody elicits cytotoxicity and suppresses migration/invasion of transitional cell carcinoma cells

International Journal of Oncology

Volumn 37, Issue 4, 2010, Pages 943-949

  Huang, Yen Ta ^a,b   Lai, Pei Chun ^a,b   Wu, Chia Chen ^b   Cheng, Chuan Chu ^b   Chiu, Ted H ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Bladder cancer; Brain derived neurotrophic factor; Transitional cell carcinoma; Tropomyosin receptor kinase B

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR ANTIBODY; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOLIPASE C GAMMA1; RECEPTOR ANTIBODY; SC 8316; SECURIN; SURVIVIN; UNCLASSIFIED DRUG; UVOMORULIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; UPREGULATION;

EID: 77956506291     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000745     Document Type: Article

References (39)

1. Heumann R: Neurotrophin signalling. Curr Opin Neurobiol 4: 668-679, 1994.
2. Lamballe F, Klein R and Barbacid M: The trk family of oncogenes and neurotrophin receptors. Princess Takamatsu Symp 22: 153-170, 1992.
3. Coulier F, Martin-Zanca D, Ernst M and Barbacid M: Mechanism of activation of the human trk oncogene. Mol Cell Biol 9: 15-23, 1989.
4. Nakagawara A: Trk receptor tyrosine kinases: A bridge between cancer and neural development. Cancer Lett 169: 107-114, 2001.
5. Scala S, Wosikowski K, Giannakakou P, et al: Brain-derived neurotrophic factor protects neuroblastoma cells from vinblastine toxicity. Cancer Res 56: 3737-3742, 1996.
6. Tanaka T, Hiyama E, Sugimoto T, Sawada T, Tanabe M and Ida N: Trk A gene expression in neuroblastoma. The clinical significance of an immunohistochemical study. Cancer 76: 1086-1095, 1995.
7. Yu X, Liu L, Cai B, He Y and Wan X: Suppression of anoikis by the neurotrophic receptor trkB in human ovarian cancer. Cancer Sci 99: 543-552, 2008.
8. Huang YT, Pei Chun Lai PC, Wu CC, Hsu SH, Cheng CC, Lan YF and Chiu TH: BDNF mediated TrkB activation is a survival signal for transitional cell carcinoma cells. Int J Oncol 36: 1469-1476, 2010.
9. Tzeng CC, Liu HS, Li C, Jin YT, Chen RM, Yang WH and Lin JS: Characterization of two urothelium cancer cell lines derived from a blackfoot disease endemic area in Taiwan. Anticancer Res 16: 1797-1804, 1996.
10. Yeh MY, Yu DS, Chen SC, Lin MS, Chang SY, Ma CP and Han SH: Establishment and characterization of a human urinary bladder carcinoma cell line (TSGH-8301). J Surg Oncol 37: 177-184, 1988.
11. Olson JM and Hallahan AR: P38 map kinase: A convergence point in cancer therapy. Trends Mol Med 10: 125-129, 2004.
12. Akhtar M, Gallagher L and Rohan S: Survivin: Role in diagnosis, prognosis, and treatment of bladder cancer. Adv Anat Pathol 13: 122-126, 2006. (Pubitemid 44341663)
13. Margulis V, Lotan Y and Shariat SF: Survivin: A promising biomarker for detection and prognosis of bladder cancer. World J Urol 26: 59-65, 2008.
14. Salehi F, Kovacs K, Scheithauer BW, Lloyd RV and Cusimano M: Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocr Relat Cancer 15: 721-743, 2008.
15. McConkey DJ, Choi W, Marquis L, et al: Role of epithelial-to-mesenchymal ransition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 28: 335-344, 2009.
16. Medina DL, Sciarretta C, Calella AM, Von Bohlen Und Halbach O, Unsicker K and Minichiello L: TrkB regulates neocortex formation through the Shc/PLCgamma-mediated control of neuronal migration. EMBO J 23: 3803-3814, 2004.
17. Nozawa H, Howell G, Suzuki S, et al: Combined inhibition of PLCγ1 and c-Src abrogates epidermal growth factor receptor-mediated head and neck squamous cell carcinoma invasion. Clin Cancer Res 14: 4336-4344, 2008.
18. Dittmar T, Husemann A, Schewe Y, Nofer JR, Niggemann B, Zanker KS and Brandt BH: Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. FASEB J 16: 1823-1825, 2002.
19. Donmez G, Sullu Y, Baris S, Yildiz L, Aydin O, Karagoz F and Kandemir B: Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas. Pathol Res Pract 205: 854-857, 2009.
20. Montano X and Djamgoz MB: Epidermal growth factor, neurotrophins and the metastatic cascade in prostate cancer. FEBS Lett 571: 1-8, 2004.
21. Yang ZF, Ho DW, Lam CT, et al: Identification of brain-derived neurotrophic factor as a novel functional protein in hepatocellular carcinoma. Cancer Res 65: 219-225, 2005.
22. Nye SH, Squinto SP, Glass DJ, et al: K-252a and staurosporine selectively block autophosphorylation of neurotrophin receptors and neurotrophin-mediated responses. Mol Biol Cell 3: 677-686, 1992.
23. Takai N, Ueda T, Nishida M, Nasu K and Narahara H: K252a is highly effective in suppressing the growth of human endometrial cancer cells, but has little effect on normal human endometrial epithelial cells. Oncol Rep 19: 749-753, 2008.
24. Kase H, Iwahashi K and Matsuda Y: K-252a, a potent inhibitor of protein kinase c from microbial origin. J Antibiot (Tokyo) 39: 1059-1065, 1986. (Pubitemid 16046365)
25. Lazarovici P, Rasouly D, Friedman L, Tabekman R, Ovadia H and Matsuda Y: K252a and staurosporine microbial alkaloid toxins as prototype of neurotropic drugs. Adv Exp Med Biol 391: 367-377, 1996. (Pubitemid 26176342)
26. Morotti A, Mila S, Accornero P, Tagliabue E and Ponzetto C: K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 21: 4885-4893, 2002.
27. Kong C, Zhu Y, Liu D, Yu M, Li S, Li Z, Sun Z and Liu G: Role of protein kinase C-alpha in superficial bladder carcinoma recurrence. Urology 65: 1228-1232, 2005.
28. Zhou X, Liu Y, You J, Zhang H, Zhang X and Ye L: Myosin light-chain kinase contributes to the proliferation and migration of breast cancer cells through cross-talk with activated ERK1/2. Cancer Lett 270: 312-327, 2008.
29. Comperat E, Roupret M, Chartier-Kastler E, et al: Prognostic value of met, ron and histoprognostic factors for urothelial carcinoma in the upper urinary tract. J Urol 179: 868-872, 2008.
30. Yu XH, Yang YX, Cai B, Yan Q, He YY and Wan XP: [anoikis-suppression and invasion induced by tyrosine kinase receptor B in OVCAR3 ovarian cancer cells]. Zhonghua Fu Chan Ke Za Zhi 43: 695-699, 2008.
31. Davis ME, Zuckerman JE, Choi CH, et al: Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature (In press).
32. Eiermann W: Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data. Ann Oncol 12 (Suppl. 1): S57-S62, 2001.
33. Geiger TR and Peeper DS: Critical role for trkb kinase function in anoikis suppression, tumorigenesis, and metastasis. Cancer Res 67: 6221-6229, 2007.
34. Ku JH, Seo SY, Kwak C and Kim HH: Cytotoxicity and apoptosis by survivin small interfering RNA in bladder cancer cells. BJU Int (In press).
35. Chao JI, Su WC and Liu HF: Baicalein induces cancer cell death and proliferation retardation by the inhibition of CD2 kinase and survivin associated with opposite role of p38 mitogen-activated protein kinase and akt. Mol Cancer Ther 6: 3039-3048, 2007.
36. Genkai N, Homma J, Sano M, Tanaka R and Yamanaka R: Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients. Oncol Rep 15: 1569-1574, 2006.
37. Kupferman ME, Jiffar T, El-Naggar A, et al: TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene (In press).
38. Wakatsuki S, Watanabe R, Saito K, Saito T, Katagiri A, Sato S and Tomita Y: Loss of human E-cadherin (ECD) correlated with invasiveness of transitional cell cancer in the renal pelvis, ureter and urinary bladder. Cancer Lett 103: 11-17, 1996.
39. Zhang L, Hu Y, Sun CY, Huang J and Chu ZB: [brain-derived neurotrophic factor promotes the secretion of MMP-9 in human myeloma cell through modulation of nucleus factor-kappaB]. Zhonghua Xue Ye Xue Za Zhi 29: 243-246, 2008.